Trends in antifungal susceptibility testing using CLSI reference and commercial methods

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 1, 2009, Pages 107-119

  Cantón, Emilia ^a   Espinel Ingroff, Ana ^b   Pemán, Javier ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alternative method; Clinical and Laboratory Standards Institute document; CLSI M27 A3; CLSI M27 S3; CLSI M38 A2; CLSI M44 A; CLSI M44 S2; Mold susceptibility testing; Yeast susceptibility testing

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANALYTIC METHOD; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; CLINICAL PROTOCOL; CONCENTRATION RESPONSE; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIUM; CULTURE TECHNIQUE; DERMATOPHYTE; DILUTION; DISK DIFFUSION; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS GROWTH; GROWTH INHIBITION; INCUBATION TIME; INVASIVE CANDIDIASIS; LOW DRUG DOSE; MALASSEZIA; MINIMUM INHIBITORY CONCENTRATION; MOULD; NONHUMAN; OROPHARYNX CANDIDIASIS; QUALITY CONTROL; REFERENCE VALUE; REPRODUCIBILITY; REVIEW; STANDARDIZATION; TREND STUDY; YEAST;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; FUNGI; GUIDELINES AS TOPIC; HUMANS; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL; REAGENT KITS, DIAGNOSTIC; REFERENCE STANDARDS; YEASTS;

EID: 69449098249     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.7.1.107     Document Type: Review

References (58)

1. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard. CLSI Document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2008).
2. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Third Informational Supplement. CLSI Document M27-S3: Clinical and Laboratory Standards Institute, Wayne, PA, USA (2008).
3. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard. CLSI Document M38-A2. Clinical Laboratory Standards Institute, Wayne, PA, USA (2008).
4. Clinical and Laboratory Standards Institute. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline. CLSI document M44-A. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2004).
5. Clinical and Laboratory Standards Institute. Zone Diameter Interpretive Standards and Corresponding Minimal Inhibitory Concentration (MIC) Interpretive Breakpoints, and Quality Control Limits for Antifungal Disk Susceptibility Testing of Yeasts; Informational Supplement. CLSI document M44-S2. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2006).
6. Espinel-Ingroff A, Cantón E. Antifungal susceptibility testing of yeasts. In: Antimicrobial Susceptibility Testing Protocols. Schwalbe S (Ed.). CRC Press, Taylor & Francis Group, NY, USA 173-207 (2007).
7. Espinel-Ingroff A, Pfaller M. Susceptibility test methods for fungi. In: Manual of Clinical Microbiology (9th Edition). Murray PR (Ed.). American Society of Microbiology, DC, USA 209-241 (2007).
8. Brown SD, Traczewski MM. Caspofungin disk diffusion breakpoints and quality control. J. Clin. Microbiol. 46(6), 1927-1929 (2008).
9. Espinel-Ingroff A, Cantón E. Antifungal susceptibility testing of filamentous fungi. In: Antimicrobial Susceptibility Testing Protocols. Schwalbe S (Ed.). CRC Press, Taylor & Francis Group, NY, USA 209-241 (2007).
10. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36(10), 2950-2956 (1998).
11. Kurtz MB, Heath IB, Marrinan J et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 38(7), 1480-1489 (1994).
12. Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. 41(1), 403-409 (2003).
13. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45(1), 327-330 (2001).
14. Odds FC, Motyl M, Andrade R et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42(8), 3475-3482 (2004).
15. Espinel-Ingroff A, Fothergill A, Ghannoum M et al. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J. Clin. Microbiol. 43(10), 5243-5246 (2005).
16. Espinel-Ingroff A, Fothergill A, Ghannoum M et al. Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds. J. Clin. Microbiol. 45(7), 2180-2182 (2007).
17. Ghannoum MA, Chaturvedi V, Espinel-Ingroff A et al. Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J. Clin. Microbiol. 42(7), 2977-2979 (2004).
18. Ghannoum MA, Arthington-Skaggs B, Chaturvedi V et al. Interlaboratory study of quality control isolates for a broth microdilution method (modified CLSI M38-A) for testing susceptibilities of dermatophytes to antifungals. J. Clin. Microbiol. 44(12), 4353-4356 (2006).
19. Espinel-Ingroff A, Pfaller M, Messer SA et al. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms. J. Clin. Microbiol. 37(3), 591-595 (1999).
20. Castro C, Serrano MC, Flores B, Espinel-Ingroff A, Martin-Mazuelos E. Comparison of the Sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38-A method to determine the activity of voriconazole against clinical isolates of Aspergillus spp. J. Clin. Microbiol. 42(9), 4358-4360 (2004).
21. Martin-Mazuelos E, Pemán J, Valverde A et al. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J. Antimicrob. Chemother. 52(3), 365-370 (2003).
22. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J. Clin. Microbiol. 45(3), 796-802 (2007).
23. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J. Clin. Microbiol. 45(11), 3522-3528 (2007).
24. Alexander BD, Byrne TC, Smith KL et al. Comparative evaluation of Etest and Sensititre YeastOne panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J. Clin. Microbiol. 45(3), 698-706 (2007).
25. Espinel-Ingroff A. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J. Clin. Microbiol. 39(4), 1360-1367 (2001).
26. Espinel-Ingroff A, Cantón E, Gibbs D, Wang A. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole. J. Clin. Microbiol. 45(3), 858-864 (2007).
27. Espinel-Ingroff A, Cantón E. Comparison of Neo-Sensitabs tablet diffusion assay with CLSI broth microdilution M38-A and disk diffusion methods for testing susceptibility of filamentous fungi with amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole. J. Clin. Microbiol. 46(5), 1793-1803 (2008).
28. Rex JH, Nelson PW, Paetznick VL et al. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42(1), 129-134 (1998).
29. Cantón E, Pemán J, Carrillo-Munoz A et al. Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods. J. Clin. Microbiol. 37(7), 2197-2200 (1999).
30. Rodriguez-Tudela JL, Donnelly JP, Pfaller MA et al. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E. Dis. 7.1) and CLSI (M27-A2). J. Clin. Microbiol. 45(1), 109-111 (2007).
31. Revankar SG, Kirkpatrick WR, McAtee RK et al. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J. Clin. Microbiol. 36(1), 153-156 (1998).
32. Ostrosky-Zeichner L, Rex JH, Pfaller MA et al. Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob. Agents Chemother. 52(11), 4175-4177 (2008).
33. Pfaller MA, Boyken LB, Hollis RJ et al. Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program. J. Clin. Microbiol. 46(11), 3585-3590 (2008).
34. Park BJ, Arthington-Skaggs B, Hajjeh RA et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents Chemother. 50(4), 1287-1292 (2006).
35. Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N et al. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J. Clin. Microbiol. 45(6), 1811-1820 (2007).
36. Pfaller MA, Messer SA, Boyken L et al. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J. Clin. Microbiol. 46(2), 551-559 (2008).
37. Pfaller MA, Messer SA, Boyken L et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by clinical and laboratory standards institute-recommended broth microdilution methods. J. Clin. Microbiol. 45(1), 70-75 (2007).
38. Pfaller MA, Messer SA, Boyken L et al. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J. Clin. Microbiol. 42(7), 3137-3141 (2004).
39. Arendrup MC, Perkhofer S, Howard SJ et al. Establishing in vitro - in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob. Agents Chemother. 52(10), 3504-3511 (2008).
40. Baixench MT, Aoun N, Desnos-Ollivier M et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59(6), 1076-1083 (2007).
41. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35(8), 982-989 (2002).
42. Cantón E, Pemán J, Viudes A et al. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn. Microbiol. Infect. Dis. 45(3), 203-206 (2003).
43. Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi MG, Walsh TJ. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J. Clin. Microbiol. 40(9), 3204-3208 (2002).
44. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J. Clin. Microbiol. 40(10), 3776-3781 (2002).
45. Meletiadis J, Antachopoulos C, Stergiopoulou T et al. Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob. Agents Chemother. 51(9), 3329-3337 (2007).
46. Rincon S, Cepero de Garcia MC, Espinel-Ingroff A. A modified Christensen's urea and CLSI broth microdilution method for testing susceptibilities of six Malassezia species to voriconazole, itraconazole, and ketoconazole. J. Clin. Microbiol. 44(9), 3429-3431 (2006).
47. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19(2), 435-447 (2006).
48. Pfaller MA, Diekema DJ, Rex JH et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44(3), 819-826 (2006).
49. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46(8), 2620-2629 (2008).
50. Rex J, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing:conceptual framework and analysis of in vitro - in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin. Infect. Dis. 24(2), 235-247 (1997).
51. Barry AL, Pfaller MA, Brown SD et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38(9), 3457-3459 (2000).
52. Krisher K, Brown SD, Traczewski MM. Quality control parameters for broth microdilution tests of anidulafungin. J. Clin. Microbiol. 42(1), 490 (2004).
53. Barry A, Bille J, Brown S et al. Quality control limits for fluconazole disk susceptibility tests on Mueller - Hinton agar with glucose and methylene blue. J. Clin. Microbiol. 41(7), 3410-3412 (2003).
54. Pfaller MA, Barry A, Bille J et al. Quality control limits for voriconazole disk susceptibility tests on Mueller - Hinton agar with glucose and methylene blue. J. Clin. Microbiol. 42(4), 1716-1718 (2004).
55. Brown S, Traczewski M. Quality control limits for posaconazole disk susceptibility tests on Mueller - Hinton agar with glucose and methylene blue. J. Clin. Microbiol. 45(1), 222-223 (2007).
56. Espinel-Ingroff A, Bartlett M, Chaturvedi V et al. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards. Antimicrob. Agents Chemother. 45(6), 1828-1835 (2001).
57. Espinel-Ingroff A, Dawson K, Pfaller M et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob. Agents Chemother. 39(2), 314-319 (1995).
58. Espinel-Ingroff A, Bartlett M, Bowden R et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35(1), 139-143 (1997).